Sinopia Biosciences Receives NCI Grant to Expand Metabolomics-Driven Drug Discovery Into Oncology
Sinopia Biosciences NCI Grant Funds LEADS Platform Application in Cancer
Sinopia Biosciences, a privately held biotechnology company headquartered at JLABS San Diego, announced in March 2026 that it has been awarded a research grant from the National Cancer Institute to apply its proprietary LEADS drug discovery platform to oncology. The Sinopia Biosciences NCI grant, issued under award number R43CA295316, follows the SBIR Phase I (R43) mechanism, which supports feasibility and proof-of-concept studies at small businesses. The exact dollar amount of the award was not disclosed in the company's announcement.
The grant names Aarash Bordbar, Ph.D., co-founder and Chief Technology Officer of Sinopia Biosciences, as the project's scientific lead. Bordbar stated in the company's press release that preliminary data had supported the application of LEADS to oncology and that the NCI funding would enable the generation of cancer-specific datasets designed for the platform's algorithms.
What the LEADS Drug Discovery Platform Does
Sinopia's LEADS (LEarn And DiScover) platform integrates high-throughput metabolomics with machine learning and systems biology to support data-driven drug discovery. The approach centers on capturing systems-level metabolic responses across biological samples, generating signatures that the company says can be used to identify therapeutic strategies and novel targets.
While sequencing-based approaches — genomics, transcriptomics — have become standard tools in modern drug discovery, metabolomics remains comparatively less explored despite its proximity to cellular phenotype and disease biology. Metabolites represent the downstream functional output of gene expression and protein activity, offering a layer of biological information that can reflect real-time cellular states. Sinopia Biosciences oncology efforts are positioned around this premise: that metabolic profiling, combined with computational analysis, can reveal intervention points that other omics approaches may miss.
The company's existing pipeline includes a lead program in Parkinson's disease, but the NCI grant marks a formal expansion of the platform into biotechnology cancer research.
NCI Grant Drug Discovery Scope and Objectives
The funded project will support the generation of large-scale datasets designed to characterize the metabolic states of hundreds of cancer types and their responses to therapeutics. A central objective is to combine high-throughput metabolomics with deep learning approaches to identify metabolic signatures associated with resistance to widely used anticancer therapies.
Drug resistance remains one of the principal challenges in clinical oncology. Tumors frequently develop mechanisms to evade the effects of chemotherapy, targeted therapy, and immunotherapy, and understanding the metabolic underpinnings of resistance could inform the development of new compounds or combination strategies. The Sinopia Biosciences NCI grant positions the company to build datasets and computational models specifically aimed at this problem.
The research will build on Sinopia's existing metabolomics datasets and models, with the goal of strengthening the platform's capacity to integrate data and machine learning for the discovery of novel targets and compounds.